Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

Hengrui Pharma, a major player in China's burgeoning biopharmaceutical sector, unveiled an impressive 91 oncology studies at the ASCO 2026 Annual Meeting in Chicago, showcasing significant clinical progress across a broad spectrum of cancers. Notably, data from trials like HELEN-Trio 011 for triple-negative breast cancer and HORIZON-CRC01 for HER2-positive colorectal cancer reported compelling improvements in pathological complete response and progression-free survival, respectively, signaling potential shifts in treatment paradigms. This robust showing underscores China's accelerating influence in global drug development, with 94 Chinese research projects, including 12 late-breaking abstracts, accepted for oral presentations at ASCO this year—a third consecutive year of growth. Hengrui's sustained investment in innovative platforms, from antibody-drug conjugate (ADC) to bispecific antibodies, positions it squarely in the global race to deliver next-generation cancer therapies, challenging established Western giants and intensifying competition. The wealth of positive data, particularly for pipeline candidates like the anti-HER2 ADC trastuzumab rezetecan and the PARP inhibitor fluzoparib, sets the stage for potential accelerated regulatory filings and market introductions in the coming years. As the oncology landscape continues its rapid evolution, global clinicians and investors will be closely watching how these promising therapies translate into tangible patient outcomes and reshape market shares, especially in highly competitive areas like breast and gastrointestinal cancers.